News & Updates
Filter by Specialty:
Show Multimedia Only

Dose reduction does not limit efficacy of trastuzumab deruxtecan in MBC
01 Oct 2025
byStephen Padilla
Reducing the dose of trastuzumab deruxtecan (T-DXd) does not have any significant effect on real-world (rw) progression-free survival (PFS) or treatment-related toxicities among patients with metastatic breast cancer (MBC), as shown in a Singapore study.
Dose reduction does not limit efficacy of trastuzumab deruxtecan in MBC
01 Oct 2025
Long COVID symptoms may persist 3 years post-infection
01 Oct 2025
byAudrey Abella
One in five COVID-19 survivors experiences at least one unresolved symptom 3 years after the initial infection, a systematic review and meta-analysis reports.







